

Clinical Trials in Australia


Dr Duncan Macinnis
Director of Stakeholder Engagement (NSW/ACT)

RACI Pharmaceutical Sciences Group (NSW) — Clinical Trials: Expertises, Collaboration and Product Supply

October 5 2022



Industry Growth Centres



OUTCOMES



Increasing collaboration and commercialisation across the sector



Improved management and workforce skills



Improved access to global supply chains and international markets



Optimising the regulatory environment

Projects Overview











Department of Industry, Science, Energy and Resources

\$15.6M

Fully committed 36 Projects

Department of Health Medical Research Future Fund

\$45M

Fully committed 39 projects

Department of Health Medical Research Future Fund

\$22.3M

Fully committed 21 projects

Department of Health Medical Research Future Fund

\$32M

8 program partners

Building the MTP workforce

Addressing skills gaps

Enhancing entrepreneurial ecosystem

Department of Health Medical Research Future Fund

\$47M

D&CVD focus

3 program partners

Establish two Research Centres

Annual funding rounds for Research Projects

Our Strategic Priorities

Priority 1	Align investment in Knowledge Priorities that meet current and future market needs
Priority 2	Create a highly productive commercialisation environment from research to proof-of-concept and early clinical trials
Priority 3	Transform the SME sub-sector to support the growth of smaller companies into larger, more stable and successful companies
Priority 4	Strengthen Australia as an attractive clinical trial research destination
Priority 5	Support the development of digital healthcare solutions: devices and data analytics
Priority 6	Position Australia as a preferred partner for international markets
Priority 7	Support advanced manufacturing as a part of the broader Australian innovation system

Strategic Funding

Garvan Molecular profiling platform


CSIRO Protein Production Platform

Ab-initio Pharma

TRI clinical trial manufacturing facility



\$15.6M committed \$26M matching 36 Projects 15 University led 22 Industry led



First patients of pioneering CAR T-cell therapy 'cured of cancer'

Cancer-killing cells still present 10 years on, with results suggesting therapy is a cure for certain blood cancers




Doug Olson still has cancer-killing cells 10 years after infusion. Photograph: AP

Two of the first human patients to be treated with a revolutionary therapy that engineers immune cells to target specific types of cancer still possess cancer-killing cells a decade later with no sign of their illness returning.



Australia's Clinical Trials Sector





Industry Growth Centres

AUSTRALIA'S CLINICAL TRIAL SECTOR



\$1.4 Billion





8,000 Jobs





95,000

PATIENTS
PARTICIPATED
in 2019



Approx.

1,880 Trials







5% Share


of GLOBAL INDUSTRY SPONSORED TRIALS

Note: * As calculated in Clinical Trials in Australia (2017 & 2021) reports






CLINICAL TRIALS – by Sponsor type




CLINICAL TRIALS – by Phase



AUSTRALIA'S SHARE OF GLOBAL-SPONSORED TRIALS — by Therapeutic area

Percentage of all multi-country trials started





- 1 Governance
- 2 Patient recruitment & economics
- Capabilities & capacity
 CTC & CRAs



Emerging opportunities

- Patient awareness, engagement & centricity
- 2 Digital evolution
- 3 Precision healthcare
- 1nnovative trial design

Priorities for the Future

- Efficiency in ethics & governance processes
- 2 Grow the clinical trials workforce & capabilities
- 3 Enhance patient recruitment
- Enhance transparency of the state of the sector

Where to next?

- Diversity in clinical trials
- Consumer engagement
- Technology in trials

> Res Involv Engagem. 2022 Feb 5;8(1):3. doi: 10.1186/s40900-022-00338-w.

A snapshot of consumer engagement in clinical trials in Australia: results of a national survey of clinical trial networks and research organisations

```
Anne McKenzie <sup>1</sup>, Janelle Bowden <sup>2</sup>, John R Zalcberg <sup>3</sup> <sup>4</sup>, Karena Conroy <sup>5</sup> <sup>6</sup>, Julia Fallon-Ferguson <sup>7</sup> <sup>8</sup>, Shilpanjali Jesudason <sup>9</sup> <sup>10</sup>, James Ansell <sup>11</sup>, Ania Anderst <sup>12</sup>, Nicola Straiton <sup>13</sup> <sup>14</sup>

Affiliations + expand
```

PMID: 35123586 PMCID: PMC8817464 DOI: 10.1186/s40900-022-00338-w

Abstract

Free PMC article

Background: Little is known about the extent, perceptions or experiences of consumers involved in clinical trials across Australia. The purpose of this National study was to better understand the activity and perceptions of clinical trial networks (CTNs), research co-ordinating centres and their consumers, around consumer involvement in clinical trials.

Drugmakers unite to set digital standards for Alzheimer's disease studies



CONTACT US FOR FURTHER

INFORMATION



Phone +61 404 859 169

Email: Duncan.macinnis@mtpconnect.org.au

GET SOCIAL







Head Office

Ground Floor, Suite 2 155 Cremorne St Cremorne, VIC 3121





MTPCONNECT. ORG.AU